I, C., GD, K., S, d. P., D, P., F, P., E, A., & S, D. F. (2018). Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: Impact on clinical status, substance craving, and quality of life. Dove Medical Press.
Cita Chicago Style (17a ed.)I, Cuomo, Kotzalidis GD, de Persis S, Piacentino D, Perrini F, Amici E, y De Filippis S. Head-to-head Comparison of 1-year Aripiprazole Long-acting Injectable (LAI) Versus Paliperidone LAI in Comorbid Psychosis and Substance Use Disorder: Impact on Clinical Status, Substance Craving, and Quality of Life. Dove Medical Press, 2018.
Cita MLA (8a ed.)I, Cuomo, et al. Head-to-head Comparison of 1-year Aripiprazole Long-acting Injectable (LAI) Versus Paliperidone LAI in Comorbid Psychosis and Substance Use Disorder: Impact on Clinical Status, Substance Craving, and Quality of Life. Dove Medical Press, 2018.